Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · September 19, 2022

Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Lacosamide in Korean Patients With Epilepsy



Additional Info

Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy
Epilepsia 2022 Aug 21;[EPub Ahead of Print], SJ Ahn, J Oh, DY Kim, H Son, S Hwang, HR Shin, EY Kim, HS Lee, WJ Lee, J Moon, ST Lee, KH Jung, KI Park, KY Jung, S Lee, KS Yu, K Chu, SK Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading